Try our mobile app

Switch to company model in classical logic    *

General information

Country: DENMARK

Sector: Biotechnology

Ascendis Pharma A/S manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes.
Website: ascendispharma.com



Growth: Good revenue growth rate 164.8%, there is acceleration compared to average historical growth rates 163.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -89.6%. On average the margin is decreasing steadily. Gross margin is high, +87.8%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of +$0.13 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 234.0% higher than minimum and 0.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.4x by EV / Sales multiple , the company can be 72.9% overvalued

Key Financials (Download financials)

Ticker: ASND
Share price, USD:  (0.0%)233.65
year average price 185.31  


year start price 119.51 2025-02-11

min close price 119.51 2025-02-11

max close price 235.39 2026-01-23

current price 233.65 2026-02-11
Common stocks: 54 131 524

Dividend Yield:  0.0%
EV / Sales: 19.9x
Margin (EBITDA LTM / Revenue): -89.6%
Fundamental value created in LTM:
Market Cap ($m): 12 648
Net Debt ($m): 350
EV (Enterprise Value): 12 998
Price to Book: -61.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-14zacks.com

Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?

2026-01-12seekingalpha.com

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-05seekingalpha.com

Ascendis: Q3 Results Validate The TransCon Platform

2025-11-25reuters.com

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

2025-11-12seekingalpha.com

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

2025-08-09seekingalpha.com

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

2025-05-01seekingalpha.com

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

2025-04-14seekingalpha.com

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

2025-04-14accessnewswire.com

Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting

2025-02-12seekingalpha.com

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND
reportedCurrency EUR EUR EUR EUR EUR EUR EUR EUR EUR USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-07 2024-09-30 2024-05-02 2024-02-07 2023-09-30 2023-06-30 2023-04-27 2022-09-30
acceptedDate 2025-11-12 16:15:33 2025-08-07 16:16:37 2025-02-12 16:15:38 2024-09-30 00:00:00 2024-05-02 16:22:05 2024-02-07 16:05:50 2024-02-07 16:15:52 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-04-27 16:01:27 2023-02-16 16:31:10 2022-09-30 00:00:00 2022-03-02 16:20:10 2021-03-10 16:50:24
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 214M 158M 364M 58M 36M 96M 267M 48M 47M 34M 51M 15M 8M 7M
costOfRevenue 22M 31M 44M 11M 11M 8M 44M 7M 13M 5M 12M 2M 4M 0
grossProfit 191M 127M 319M 47M 25M 88M 222M 41M 34M 29M 39M 14M 4M 7M
grossProfitRatio 0.895 0.801 0.806 0.682 0.921 0.846 0.727 0.862 0.889
researchAndDevelopmentExpenses 67M 72M 307M 74M 83M 71M 413M 111M 105M 106M 380M 97M 296M 261M
generalAndAdministrativeExpenses 0 106M 285M 68M 72M 0 259M 0 0 0 216M 0 0 0
sellingAndMarketingExpenses 0 0 0 0 2M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 113M 106M 285M 68M 74M 67M 259M 64M 70M 67M 216M 61M 160M 77M
otherExpenses 0 2M 7M 2M 0 0 6M 0 0 0 5M 0 0 0
operatingExpenses 180M 180M 598M 143M 158M 137M 678M 175M 175M 173M 601M 158M 456M 338M
costAndExpenses 203M 211M 642M 155M 169M 145M 722M 182M 188M 177M 613M 160M 460M 338M
interestIncome 0 55M 14M 28M 49M 4M 17M 4M 36M 45M 7M 20M 692 000 2M
interestExpense 0 33M 66M 25M 20M 77M 44M 25M 9M 10M 31M 41M 4M 2M
depreciationAndAmortization 4M 4M 18M 2M 2M 5M 19M 5M 5M 48M 18M 21M 15M 9M
ebitda -53M 2M -290M -71M -88M -47M -411M -132M -108M -95M -529M -123M -365M -408M
ebitdaratio -0.25 0.015 -1.23 -2.431 -0.489 -2.755 -2.276 -2.835 -8.068
operatingIncome 11M -53M -279M -97M -133M -49M -456M -134M -141M -144M -562M -145M -452M -331M
operatingIncomeRatio 0.051 -0.335 -1.673 -3.702 -0.512 -2.798 -2.972 -4.278 -9.451
totalOtherIncomeExpensesNet -68M 18M -94M -1M 24M -79M -19M -7M -7M 34M -16M -25M 68M -89M
incomeBeforeTax -57M -35M -373M -98M -109M -129M -474M -162M -122M -110M -578M -169M -384M -419M
incomeBeforeTaxRatio -0.269 -0.222 -1.698 -3.032 -1.34 -3.364 -2.571 -3.263 -11.061
incomeTaxExpense 4M 4M 5M 1M 229 000 3M 7M 645 000 -429 000 1M 5M -167 000 -367 000 -219 000
netIncome -61M -39M -378M -99M -109M -131M -481M -162M -121M -111M -583M -169M -384M -419M
netIncomeRatio -0.285 -0.246 -1.715 -3.039 -1.366 -3.377 -2.562 -3.302 -11.05
eps -1 -0.64 -6.53 0 -1.91 -2.3 -8.55 -2.88 -2.16 -1.98 -10.4 -3.03 -7 -8.28
epsdiluted -1 -0.82 0 -1.91 -2.3 -2.88 -2.16 -1.98 -3.03
weightedAverageShsOut 61M 60M 58M 0 57M 57M 56M 56M 56M 56M 56M 56M 55M 51M
weightedAverageShsOutDil 61M 64M 58M 0 57M 57M 56M 56M 56M 56M 56M 56M 55M 51M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-12 2024-02-07 2023-02-16 2022-03-02 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -51M -27M -23M -3M -106 000
ebit -308M -430M -547M -380M -417M
nonOperatingIncomeExcludingInterest 29M -25M -15M -72M 87M
netIncomeFromContinuingOperations -378M -481M -583M -384M -419M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -378M -481M -583M -384M -419M
epsDiluted -6.53 -8.55 -10.4 -7 -8.28

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND
reportedCurrency EUR EUR EUR EUR EUR EUR EUR EUR EUR USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-07 2024-09-30 2024-05-02 2024-02-07 2023-09-30 2023-06-30 2023-04-27 2022-09-30
acceptedDate 2025-11-12 16:15:33 2025-08-07 16:16:37 2025-02-12 16:15:38 2024-09-30 00:00:00 2024-05-02 16:22:05 2024-02-07 16:05:50 2024-02-07 16:15:52 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-04-27 16:01:27 2023-02-16 16:31:10 2022-09-30 00:00:00 2022-03-02 16:20:10 2021-03-10 16:50:24
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 539M 494M 560M 626M 259M 320M 392M 441M 394M 501M 445M 608M 446M 585M
shortTermInvestments 0 0 0 0 0 0 7M 14M 37M 84M 291M 311M 236M 134M
cashAndShortTermInvestments 539M 494M 560M 626M 259M 320M 399M 455M 431M 586M 735M 920M 682M 719M
netReceivables 135M 110M 166M 50M 81M 41M 36M 50M 36M 35M 12M 22M 2M 387 000
inventory 302M 303M 296M 265M 251M 233M 209M 189M 168M 151M 131M 104M 75M 0
otherCurrentAssets 42M 45M 11M 32M 37M 70M 20M 38M 43M 39M 14M 35M 21M 7M
totalCurrentAssets 1 018M 953M 1 061M 974M 627M 664M 703M 733M 678M 810M 923M 1 080M 806M 740M
propertyPlantEquipmentNet 102M 94M 99M 98M 104M 107M 111M 126M 125M 128M 129M 139M 126M 108M
goodwill 0 0 3M 0 0 0 3M 0 0 0 3M 0 3M 3M
intangibleAssets 4M 4M 533 000 0 4M 4M 924 000 4M 0 0 1M 0 2M 2M
goodwillAndIntangibleAssets 4M 4M 4M 4M 4M 4M 4M 4M 5M 5M 5M 5M 5M 6M
longTermInvestments 28M 35M 14M 16M 23M 25M 6M 8M 14M 22M 30M 47M 146M 124M
taxAssets 0 0 0 0 -2M 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 3M 2M 2M 63 639 2M 2M 2M 2M 2M 2M 2M 2M 1M
totalNonCurrentAssets 137M 135M 119M 120M 131M 138M 123M 140M 146M 156M 166M 194M 279M 240M
otherAssets 0 0 0 0 -77 016 0 0 0 0 0 0 0 0 0
totalAssets 1 155M 1 088M 1 179M 1 094M 758M 803M 826M 873M 824M 966M 1 090M 1 273M 1 085M 980M
accountPayables 79M 94M 96M 75M 100M 95M 95M 122M 122M 131M 101M 86M 59M 22M
shortTermDebt 482M 462M 492M 450M 454M 439M 421M 26M 27M 25M 413M 20M 7M 0
taxPayables 0 0 1M 1M 1M 3M 2M 6M 6M 7M 5M 126 000 198 000 301 000
deferredRevenue 4M 2M 936 000 2M 0 1M 1M 4M 4M 10M 0 3M 3M 363 000
otherCurrentLiabilities 421M 377M 318M 311M 294M 262M 203M 61M 39M 32M 183M 34M 24M 23M
totalCurrentLiabilities 986M 935M 908M 838M 848M 799M 737M 213M 192M 198M 717M 143M 100M 53M
longTermDebt 331M 330M 365M 339M 219M 230M 223M 640M 479M 480M 95M 533M 98M 0
deferredRevenueNonCurrent 692 000 692 000 5M 5M 5M 5M 6M 949 000 949 000 4M 14M 13M 3M 0
deferredTaxLiabilitiesNonCurrent 10M 10M 7M 9M 8M 7M 6M 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 -85M 93M 86M 117M -95M 570M -98M 3M
totalNonCurrentLiabilities 342M 340M 377M 353M 232M 242M 235M 734M 567M 601M 110M 679M 101M 88M
otherLiabilities 0 0 0 0 -498 482 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 99M 105M 0 0 109M 0 105M 92M
totalLiabilities 1 329M 1 275M 1 285M 1 191M 1 079M 1 041M 971M 947M 759M 799M 826M 822M 201M 141M
preferredStock 0 0 0 0 0 239M 0 76M 0 0 0 0 0 0
commonStock 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 7M
retainedEarnings -2 705M -2 666M -2 560M -2 547M -2 474M -2 393M -2 277M -2 208M 0 0 -1 860M 0 -1 236M -1 030M
accumulatedOtherComprehensiveIncomeLoss -1M 309 000 2M 953 000 -329M -246M 720 999 -81M 57M 160M 3M 444M 4M 133M
othertotalStockholdersEquity 2 524M 2 470M 2 441M 2 474M 2 393M 2 132M 0 0 0
totalStockholdersEquity -174M -188M -106M -97M -321M -238M -146M -73M 65M 167M 263M 452M 884M 839M
totalEquity -174M -188M -106M -97M -321M -238M -146M -73M 65M 167M 263M 452M 884M 839M
totalLiabilitiesAndStockholdersEquity 1 155M 1 088M 1 094M 758M 803M 873M 824M 966M 1 273M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 155M 1 088M 1 179M 1 094M 758M 803M 826M 873M 824M 966M 1 090M 1 273M 1 085M 980M
totalInvestments 28M 35M 14M 16M 23M 25M 13M 22M 51M 106M 321M 359M 382M 259M
totalDebt 814M 793M 857M 789M 673M 669M 743M 666M 506M 505M 618M 553M 210M 92M
netDebt 275M 298M 297M 163M 414M 349M 351M 225M 112M 4M 173M -55M -236M -493M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-12 2024-02-07 2023-02-16 2022-03-02 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 166M 36M 12M 2M 387 000
otherReceivables 0 0 0 0 0
prepaids 28M 39M 32M 25M 14M
totalPayables 98M 97M 107M 60M 22M
otherPayables 1M 2M 5M 198 000 301 000
accruedExpenses 0 0 0 0 0
capitalLeaseObligationsCurrent 0 14M 14M 7M 7M
capitalLeaseObligationsNonCurrent 0 85M 95M 98M 85M
treasuryStock -113 000 -146 000 -149 000 -21 000 0
additionalPaidInCapital 2 444M 2 123M 2 113M 2 108M 1 729M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND ASND
reportedCurrency EUR EUR EUR EUR EUR EUR EUR EUR USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-07 2024-05-02 2024-02-07 2023-09-30 2023-06-30 2023-04-27 2022-09-30
acceptedDate 2025-11-12 16:15:33 2025-08-07 16:16:37 2025-02-12 16:15:38 2024-05-02 16:22:05 2024-02-07 16:05:50 2024-02-07 16:15:52 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-04-27 16:01:27 2023-02-16 16:31:10 2022-09-30 00:00:00 2022-03-02 16:20:10 2021-03-10 16:50:24
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -61M -39M -378M -109M -131M -481M -162M -121M -111M -583M -169M -384M -419M
depreciationAndAmortization 4M 4M 18M 4M 4M 19M 5M 5M 5M 18M 5M 15M 9M
deferredIncomeTax 4M 4M 5M 0 3M 0 645 000 -429 000 1M 5M -167 000 -367 000 -219 000
stockBasedCompensation 31M 30M 96M 26M 17M 67M 17M 20M 14M 64M 14M 67M 53M
changeInWorkingCapital 25M -44M -107M -24M -52M -96M -24M -35M -26M -12M 25M -48M -964 000
accountsReceivables -25M -48M -119M -11M -11M -33M -14M 0 -9608 -12M 0 -7M -2M
inventory 1M -10M -87M -19M -24M -78M -21M -17M -20M -55M -3M -75M 0
accountsPayables 0 0 0 9M -19M 0 4M 0 0 0 0 0 0
otherWorkingCapital 48M 14M 98M -3M 6M 15M 7M -17M -6M 54M 28M 34M 1M
otherNonCashItems 229 000 37M 61M 42M 49M 25M 39M -21M -30M 12M 27M -68M 86M
netCashProvidedByOperatingActivities 2M -7M -306M -61M -102M -467M -125M -153M -147M -496M -99M -418M -272M
investmentsInPropertyPlantAndEquipment -53 000 -4M -1M -342 000 -199 000 -2M -976 000 -444 000 -1M -14M -3M -24M -20M
acquisitionsNet 0 0 0 0 0 0 47 341 0 0 0 0 -10M 0
purchasesOfInvestments 0 0 0 0 0 0 -47 341 0 0 -214M -71M -226M -538M
salesMaturitiesOfInvestments 0 0 7M 0 7M 0 23M 47M 212M 281M 88M 150M 263M
otherInvestingActivites 0 0 950 000 7M 46 000 0 0 0
netCashUsedForInvestingActivites -53 000 -4M 608 000 7M 22M 47M 211M 14M
debtRepayment -7M -5M -3M -3M -3M -3M -3M -1M
commonStockIssued 0 0 263 703 21M 6M 0 0 0
commonStockRepurchased 0 0 0 0 0 -2M 0 0 0 -105M 1000 -22M 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 45M 12M 365 000 21M 140M 208 000 2M 1M
netCashUsedProvidedByFinancingActivities 39M 7M -2M 18M 143M -2M -702 000 -76 000
effectOfForexChangesOnCash 4M -19M 23M 2M 4M -6M 6M 1M -6M 36M 21M 39M -53M
netChangeInCash 45M -24M 167M -62M -72M -53M 47M -107M 57M -2M -64M -138M -14M
cashAtEndOfPeriod 539M 494M 560M 259M 320M 392M 441M 394M 501M 445M 608M 446M 585M
cashAtBeginningOfPeriod 494M 518M 392M 320M 392M 445M 394M 501M 445M 446M 672M 585M 598M
operatingCashFlow 2M -7M -306M -61M -102M -467M -125M -153M -147M -496M -99M -418M -272M
capitalExpenditure -53 000 -4M -1M -342 000 -199 000 -2M -976 000 -444 000 -1M -14M -3M -24M -22M
freeCashFlow 2M -12M -308M -62M -102M -470M -126M -154M -148M -510M -102M -442M -293M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-12 2024-02-07 2023-02-16 2022-03-02 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 950 000 289M 10M -530 000 3M
netCashProvidedByInvestingActivities 7M 286M 62M -111M -291M
netDebtIssuance 123M 126M 497M -6M -5M
longTermNetDebtIssuance 123M 126M 497M -6M -5M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 310M -2M -105M 346M 581M
netCommonStockIssuance 310M -2M -105M 346M 581M
commonStockIssuance 310M 0 0 368M 581M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 11M 10M 5M 12M 27M
netCashProvidedByFinancingActivities 444M 134M 397M 351M 603M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 16M 0 0 0

Earning call transcript

2025 q3
2025-11-12 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-12 ET (fiscal 2024 q4)
2024 q3
2024-11-14 ET (fiscal 2024 q3)
2024 q2
2024-09-03 ET (fiscal 2024 q2)
2024 q1
2024-05-04 ET (fiscal 2024 q1)
2023 q4
2024-02-07 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-09-05 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-04 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 6
2026-01-14 21:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-01-14 21:15 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-01-12 11:04 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2026-01-08 18:26 ET
Ascendis Pharma published news for 2025 q4
SEC form 6
2025-12-30 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-12-30 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-12-10 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-12-10 21:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-26 02:47 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:39 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:39 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:15 ET
Ascendis Pharma reported for 2025 q3
SEC form 6
2025-11-12 16:05 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-11-12 16:05 ET
Ascendis Pharma reported for 2025 q3
SEC form 6
2025-10-22 21:00 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-10-15 20:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-10-15 20:15 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-10-08 20:13 ET
Ascendis Pharma published news for 2025 q3
SEC form 6
2025-09-30 20:02 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-09-30 20:02 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-09-10 20:04 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-09-10 20:04 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-13 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-13 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-07 20:16 ET
Ascendis Pharma reported for 2025 q2
SEC form 6
2025-08-07 20:05 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-08-07 20:05 ET
Ascendis Pharma reported for 2025 q2
SEC form 6
2025-07-28 11:15 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-07-09 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-07-09 20:01 ET
Ascendis Pharma published news for 2025 q2
SEC form 6
2025-06-27 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-27 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-11 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-11 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-09 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-09 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-09 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-06-02 12:06 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-28 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-28 20:03 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-14 20:00 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-14 20:00 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-01 20:46 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-05-01 20:46 ET
Ascendis Pharma reported for 2025 q1
SEC form 6
2025-05-01 20:15 ET
Ascendis Pharma reported for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-29 20:05 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-09 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-04-09 20:01 ET
Ascendis Pharma published news for 2025 q1
SEC form 6
2025-03-31 20:01 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-28 20:01 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-28 20:01 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-20 20:17 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-12 20:48 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-03-12 20:48 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 20
2025-02-12 16:15 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 16:12 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 16:07 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 16:07 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 15:24 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2025-02-12 15:24 ET
Ascendis Pharma published news for 2024 q4
SEC form 6
2024-11-14 16:19 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-11-14 16:19 ET
Ascendis Pharma reported for 2024 q3
SEC form 6
2024-11-14 00:00 ET
Ascendis Pharma reported for 2024 q3
SEC form 6
2024-11-13 16:02 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-11-13 16:02 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-11-04 07:05 ET
Ascendis Pharma published news for 2024 q3
SEC form 6
2024-09-03 17:14 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-09-03 17:11 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-09-03 17:11 ET
Ascendis Pharma reported for 2024 q2
SEC form 6
2024-09-03 00:00 ET
Ascendis Pharma reported for 2024 q2
SEC form 6
2024-08-14 16:02 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-08-14 16:02 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-08-12 07:05 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-07-10 16:01 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-07-10 16:01 ET
Ascendis Pharma published news for 2024 q2
SEC form 6
2024-06-28 06:07 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-06-28 06:07 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-06-12 16:01 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-06-12 16:01 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:29 ET
Ascendis Pharma reported for 2024 q1
SEC form 6
2024-05-02 16:22 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:22 ET
Ascendis Pharma reported for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-05-02 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-04-24 09:16 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-04-10 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-04-10 16:02 ET
Ascendis Pharma published news for 2024 q1
SEC form 6
2024-03-27 16:01 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-03-27 16:01 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-03-14 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-03-14 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-29 16:21 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-14 16:07 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-14 16:07 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-07 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-02-07 16:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 20
2024-02-07 00:00 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-31 16:01 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-29 08:36 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-10 16:02 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-10 16:02 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-08 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-08 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-08 06:05 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-02 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2024-01-02 06:08 ET
Ascendis Pharma published news for 2023 q4
SEC form 6
2023-11-07 16:03 ET
Ascendis Pharma published news for 2023 q3
SEC form 6
2023-11-07 16:01 ET
Ascendis Pharma published news for 2023 q3
SEC form 6
2023-10-11 16:01 ET
Ascendis Pharma published news for 2023 q3
SEC form 6
2023-09-29 16:01 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-14 12:42 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-13 16:01 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:15 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:14 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:09 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-09-05 16:05 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-08-09 16:01 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-07-12 16:02 ET
Ascendis Pharma published news for 2023 q2
SEC form 6
2023-06-30 16:06 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-20 08:05 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-20 08:00 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-14 16:01 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-05 17:32 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-06-01 16:03 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-05-31 12:01 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-05-31 08:35 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-04-27 00:00 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-04-03 08:02 ET
Ascendis Pharma published news for 2023 q1
SEC form 6
2023-03-30 16:03 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-03-15 16:02 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-03-13 07:15 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-03-01 16:03 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-02-16 16:31 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-02-16 16:01 ET
Ascendis Pharma published news for 2022 q4
SEC form 20
2023-02-16 00:00 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-02-15 16:01 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-11 16:02 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-09 08:03 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-09 08:00 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2023-01-03 16:02 ET
Ascendis Pharma published news for 2022 q4
SEC form 6
2022-12-14 16:03 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-12-05 08:06 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-14 08:05 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-14 08:01 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-14 07:06 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-09 16:04 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-02 16:05 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-11-02 00:00 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-10-31 08:11 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-10-12 16:02 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-10-03 09:00 ET
Ascendis Pharma published news for 2022 q3
SEC form 6
2022-09-30 16:02 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-09-14 16:06 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-09-12 16:06 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-31 16:05 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-12 16:01 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-10 16:18 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-10 16:08 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-08-10 00:00 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-07-13 17:04 ET
Ascendis Pharma published news for 2022 q2
SEC form 6
2022-06-30 16:01 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-06-15 16:03 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-06-02 16:01 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-23 08:30 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-11 16:14 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-11 16:01 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-11 00:00 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-02 06:25 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-05-02 06:19 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-04-13 16:12 ET
Ascendis Pharma published news for 2022 q1
SEC form 6
2022-03-31 17:53 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-29 17:01 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-14 08:01 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-14 06:07 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-09 16:33 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-02 16:20 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-03-02 16:13 ET
Ascendis Pharma published news for 2021 q4
SEC form 20
2022-03-02 00:00 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-02-09 14:03 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-13 08:12 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-12 15:37 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-10 08:24 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-10 08:20 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2022-01-04 13:42 ET
Ascendis Pharma published news for 2021 q4
SEC form 6
2021-12-15 18:03 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-12-15 11:45 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-12-13 16:53 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-18 16:57 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-18 16:01 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-12 13:04 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-10 17:23 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-10 16:11 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-11-10 00:00 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-21 06:06 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-15 08:30 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-13 21:45 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-10-01 16:01 ET
Ascendis Pharma published news for 2021 q3
SEC form 6
2021-09-22 17:10 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-09-15 21:45 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-09-07 17:12 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-09-07 16:55 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-27 00:00 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-25 21:51 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-25 21:49 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-08-12 16:02 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-07-15 16:02 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-07-06 08:31 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-07-01 16:05 ET
Ascendis Pharma published news for 2021 q2
SEC form 6
2021-06-14 09:00 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-06-11 17:31 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-06-10 16:02 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-28 17:17 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-27 00:00 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-12 21:45 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-12 16:36 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-11 06:08 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-05-11 06:01 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-04-30 17:23 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-04-14 21:07 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-04-01 17:10 ET
Ascendis Pharma published news for 2021 q1
SEC form 6
2021-03-10 16:50 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-03-10 16:21 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-03-09 17:27 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-02-10 19:49 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-01-13 16:08 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-01-11 06:17 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2021-01-11 06:09 ET
Ascendis Pharma published news for 2020 q4
SEC form 6
2020-12-31 06:09 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-12-30 16:06 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-12-14 16:30 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-12-11 17:13 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-11-20 12:01 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-11-12 06:13 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-11-12 06:11 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-10-23 09:47 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-10-15 18:11 ET
Ascendis Pharma published news for 2020 q3
SEC form 6
2020-10-05 16:04 ET
Ascendis Pharma published news for 2020 q3